Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies

被引：0
|
作者：
Daud, A.
Schmitt, M.
Marchion, D.
Bicaku, E.
Minton, S.
Egorin, M.
Zwiebel, J.
Chiappori, A.
Sullivan, D.
Munster, P.
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3502
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I trial of a sequence-specific combination of the HDAC inhibitor, valproic acid (VPA), and the topoisomerase II inhibitor, epirubicin, in advanced solid tumors: Clinical results and correlative studies.
    Munster, P. N.
    Marchion, D. C.
    Bicaku, E.
    Schmitt, M. L.
    Padilla, B.
    Stauffer, P.
    Garrett, C.
    Chiappori, A.
    Sullivan, D. M.
    Daud, A. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 137S - 137S
  • [2] Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.
    Park, Haeseong
    Garrido-Laguna, Ignacio
    Naing, Aung
    Fu, Siqing
    Falchook, Gerald Steven
    Piha-Paul, Sarina Anne
    Wheler, Jennifer J.
    Hong, David S.
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Kaseb, Ahmed Omar
    Oki, Yasuhiro
    Zinner, Ralph
    Patel, Shreyaskumar
    Bravo, Vivianne Marie Velez
    Fanale, Michelle A.
    Meric-Bernstam, Funda
    Kurzrock, Razelle
    Janku, Filip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922).
    Ramalingam, S.
    Parise, R. A.
    Egorin, M. J.
    Argiris, A.
    Stoller, R.
    Beattie, L.
    Aparicio, A.
    Newman, E. M.
    Zwiebel, J.
    Belani, C. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 98S - 98S
  • [4] Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Ramalingam, Suresh S.
    Parise, Robert A.
    Ramananthan, Ramesh K.
    Lagattuta, Theodore F.
    Musguire, Lori A.
    Stoller, Ronald G.
    Potter, Douglas M.
    Argiris, Athanassios E.
    Zwiebel, James A.
    Egorin, Merrill J.
    Belani, Chandra P.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (12) : 3605 - 3610
  • [5] A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    William R. Schelman
    Anne M. Traynor
    Kyle D. Holen
    Jill M. Kolesar
    Steven Attia
    Tien Hoang
    Jens Eickhoff
    Zhisheng Jiang
    Dona Alberti
    Rebecca Marnocha
    Joel M. Reid
    Matthew M. Ames
    Renee M. McGovern
    Igor Espinoza-Delgado
    John J. Wright
    George Wilding
    Howard H. Bailey
    [J]. Investigational New Drugs, 2013, 31 : 1539 - 1546
  • [6] A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
    Schelman, William R.
    Traynor, Anne M.
    Holen, Kyle D.
    Kolesar, Jill M.
    Attia, Steven
    Hoang, Tien
    Eickhoff, Jens
    Jiang, Zhisheng
    Alberti, Dona
    Marnocha, Rebecca
    Reid, Joel M.
    Ames, Matthew M.
    McGovern, Renee M.
    Espinoza-Delgado, Igor
    Wright, John J.
    Wilding, George
    Bailey, Howard H.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1539 - 1546
  • [7] Combined autophagy and HDAC inhibition A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors
    Mahalingam, Devalingam
    Mita, Monica
    Sarantopoulos, John
    Wood, Leslie
    Amaravadi, Ravi K.
    Davis, Lisa E.
    Mita, Alain
    Curiel, Tyler J.
    Espitia, Claudia M.
    Nawrocki, Steffan T.
    Giles, Francis J.
    Carew, Jennifer S.
    [J]. AUTOPHAGY, 2014, 10 (08) : 1403 - 1414
  • [8] Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
    James, Edward Samuel
    Chung, Gina
    Sowers, Noelle Marie
    Clark, Mary Beth
    Lilian, Rebecca
    Abraham, Gineesha
    Chmael, Susan
    Cappiello, Michelle
    DiGiovanna, Michael
    Hofstatter, Erin Wysong
    Sanft, Tara Beth
    Israel, Gary M.
    Pusztai, Lajos
    Harris, Lyndsay
    Abu-Khalaf, Maysa M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [9] A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia
    How, Jonathan
    Minden, Mark D.
    Brian, Leber
    Chen, Eric X.
    Brandwein, Joseph
    Schuh, Andre C.
    Schimmer, Aaron D.
    Gupta, Vikas
    Webster, Sheila
    Degelder, Tammy
    Haines, Patricia
    Stayner, Lee-Anne
    McGill, Shauna
    Wang, Lisa
    Piekarz, Richard
    Wong, Tracy
    Siu, Lillian L.
    Espinoza-Delgado, Igor
    Holleran, Julianne L.
    Egorin, Merrill J.
    Yee, Karen W. L.
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2793 - 2802
  • [10] Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
    James, Edward Samuel
    Chung, Gina G.
    DiGiovanna, Michael
    Sanft, Tara Beth
    Hofstatter, Erin Wysong
    Sowers, Noelle
    Clark, Mary Beth
    Lilian, Rebecca
    Chmael, Susan
    Cappiello, Michelle
    Abraham, Gineesha
    Israel, Gary M.
    Pusztai, Lajos
    Harris, Lyndsay
    Abu-Khalaf, Maysa M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345